TINN2 is a European research network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Programme of the 7 th Framework Programme.

News & Events


TINN European Survey on the Use of Antibiotics in NICUs

The survey results are now available and the published article has been published.

Please click here to consult it.


MANY THANKS to all the Neonatal Intensive Care Units that dedicated their time to partipate in the TINN2 survey.


Consortium final meeting on 8th October 2015, in Paris, France

The official event of the TINN2 FP7 European Research Project was organised by Inserm-Transfert on 8th October 2015 in Paris (France).

This meeting gathered together all TINN2 partners for presenting and discussing the latest progresses within TINN2 activities, a project on preclinical studies and paediatric investigation plans for children, under the coordination of the French National Institute of Health and Medical Research (Inserm).

European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom 31st to 4th April 2012


TINN2 Project was presented on Poster at the ECCMID congress in London, United Kingdom.

Brochure PDF :

Univerity of Ulm

The University Ulm is a public university with the medical faculty and university medical hospital providing all specialities of medicine. The section of clinical pharmacology is part of the university hospital and is involved in several aspects of drug therapy, ethical review board of the university as well as in organization and performance of clinical studies mainly in the field of pharmacogenetics.

The section of clinical pharmacology within the institute of pharmacology of natural compounds and clinical pharmacology has labs for pharmacogenetics diagnostics providing the equipment necessary for diagnostics of all kind of variants within the genomic DNA. Most common methods used are DNA sequencing, realtime PCR, PCR RFLP. In addition, methods for quantitative PCR for gene expression studies are available and being used.

Prof. Stingl has done research in pharmacogenetics since many years. Her special expertise is the design of clinical studies on pharmacogenetics polymorphisms in humans. She worked a lot on genetic variability in drug metabolism but also on genetic influence factors of drug response. She also designed and organized clinical studies and is a partner in two national multicentric studies, one on individualization of isoniazide treatment of tuberculosis and one on the efficacy of St. Johns Wort in children. She is involved as coordinator of clinical work on another EU funded project on oral anticoagulation treatment. Her lab contains different equipments for pharmacogenetics diagnostics such as real-time PCR, DNA sequencer, agarose gel-electrophoresis and several thermocyclers. She has large experience in pharmacogenetics data analysis and development of databases for pharmacogenetics data evaluation in large cohorts.


Back to the list of institutions